1784463-68-8 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 5-chlorothiazole-4-carboxylate is used as a key intermediate in the synthesis of pharmaceuticals for its potential applications in developing new drugs. Its reactivity and versatility allow for the creation of diverse heterocyclic compounds, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, methyl 5-chlorothiazole-4-carboxylate serves as an essential building block for the development of agricultural products. Its role as an intermediate in the preparation of various heterocyclic compounds aids in the innovation of effective and sustainable agrochemical solutions.
Used in Organic Synthesis:
Methyl 5-chlorothiazole-4-carboxylate is utilized as a versatile reagent in organic synthesis, enabling the production of a wide range of chemical compounds. Its high reactivity makes it a preferred choice for researchers and chemists working on the development of novel molecules with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1784463-68-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,8,4,4,6 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1784463-68:
(9*1)+(8*7)+(7*8)+(6*4)+(5*4)+(4*6)+(3*3)+(2*6)+(1*8)=218
218 % 10 = 8
So 1784463-68-8 is a valid CAS Registry Number.
1784463-68-8Relevant academic research and scientific papers
2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS
-
, (2021/06/26)
2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).
